Fibrocell announces gene therapy collaboration with Castle Creek Pharmaceuticals
Fibrocell Science announced the completion of a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for treatment of recessive dystrophic epidermolysis bullosa, a rare, life-threatening genetic disorder. April 15, 2019